Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3960 - Cyclin D1 differential activation and its prognostic impact among advanced breast cancer patients treated with trastuzumab.

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Giannis Mountzios

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

G. Mountzios, V. Kotoula, G. Koliou, K. Papadopoulou, G. Lazaridis, C. Christodoulou, G. Pentheroudakis, M. Skondra, A. Koutras, H. Linardou, E. Razis, P. Papakostas, S. Chrisafi, G. Aravantinos, I. Nicolaou, A. Goussia, K.T. Kalogeras, D.G. Pectasides, G. Fountzilas

Author affiliations

  • Data Office, Hellenic Cooperative Oncology Group (HeCOG), 11524 - Athens/GR
More

Resources

Abstract 3960

Background

The cyclin D1-mediated molecular pathway depicts significant cross-talk with the ER/PR and HER2 pathways in patients with advanced breast cancer and these correlations may have clinical implications. We sought to determine the level of activation of the critical components of the cyclin D1-mediated pathway and to evaluate their prognostic significance across the different molecular subtypes of advanced breast cancer.

Methods

The study population included 219 trastuzumab-treated women with advanced breast cancer who had been found to have HER2-positive disease by local testing. For all tumors, central testing for HER2 was performed and cyclin D1 (CCND1) gene amplification and mRNA and protein expression were assessed by FISH, qRT-PCR and IHC, respectively.

Results

Only 134 of the 219 patients (61.2%) were HER2-positive (HER2 gene amplification and/or 3+ HER2 protein expression). After a median follow-up of 136.0 months, 105 HER2-positive patients (78.4%) and 76 HER2-negative patients (89.4%) had died, while 80.0% of the former and 87.1% of the latter had disease progression. Median PFS was 14.0 months for HER2-positive and 8.9 months for HER2-negative patients, while median survival was 48.1 months and 35.0 months, respectively. Cyclin D1 mRNA expression was higher in patients with positive ER/PgR. Cyclin D1 (as assessed by FISH, qRT-PCR and IHC) did not reach significance in terms of PFS or survival either in the entire study population or in HER2-positive patients. In the HER2-negative subgroup, negative cyclin D1 protein expression was associated with higher risk of progression (HR = 1.66, 95% CI 1.01-2.72, Wald’s p = 0.045), while in de novo metastatic patients, the risk of progression was higher for patients with non-amplified CCND1 tumors (HR = 2.00 95% CI 1.03-3.90, p = 0.041).

Conclusions

Aberrant activation of the cyclin D1-mediated pathway appears to reduce the risk of progression in HER2-negative tumors, but not in HER2-positive ones. If our results are validated by larger prospective trials, further evaluation of the cyclin D1-mediated pathway might identify prognostic and therapeutic implications in patients with advanced breast cancer.

Clinical trial identification

Legal entity responsible for the study

Hellenic Cooperative Oncology Group (HeCOG).

Funding

Roche, Hellenic Cooperative Oncoogy Group.

Editorial Acknowledgement

NA

Disclosure

G. Mountzios, C. Christodoulou, P. Papakostas: Honoraria: Roche; Advisory role: Roche. G. Lazaridis: Honoraria: Roche. A. Koutras, G. Fountzilas: Advisory role: Roche. E. Razis: Advisory role, travel, honoraria: Roche; Research funding: Roche/Genentech. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.